Patent classifications
A61K31/42
ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
The present invention provides compounds of Formula I:
##STR00001##
pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
The present invention provides compounds of Formula I:
##STR00001##
pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
The present invention provides compounds of Formula I,
##STR00001##
pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
The present invention provides compounds of Formula I,
##STR00001##
pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
The present invention provides compounds of Formula I,
##STR00001##
pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
The present invention provides compounds of Formula I,
##STR00001##
pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
Compositions and methods for cancer treatment
The invention described herein pertains to the use of oxazolidinone antibiotics, alone or in combination, in the treatment of cancer. In particular, the invention pertains to the treatment of malignant gliomas, thyroid cancer or melanoma, or borderline forms of malignant glioma, thyroid cancer or melanoma.
Compositions and methods for cancer treatment
The invention described herein pertains to the use of oxazolidinone antibiotics, alone or in combination, in the treatment of cancer. In particular, the invention pertains to the treatment of malignant gliomas, thyroid cancer or melanoma, or borderline forms of malignant glioma, thyroid cancer or melanoma.
Gamma-diketones for treatment and prevention of aging skin and wrinkles
The present disclosure relates to compounds, cosmetic or dermopharmaceutical compositions comprising the same, and methods for using the compounds or compositions for treating, protecting, and/or improving the condition and/or aesthetic appearance of skin, for example, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, or improving the appearance of fine lines and/or or wrinkles of skin comprising application of the compounds or compositions disclosed. In some embodiments, the compounds useful in the methods described herein include compounds of Formula I: ##STR00001##
or a dermatologically acceptable salt thereof.
Methods for Treatment of Stroke or Cerebrovascular Accidents Using an ETB Receptor Agonist
Methods of using an ET.sub.B receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ET.sub.B receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.